Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Oncol Rep

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    November 2021
  1. ZENG Y, Lv X, Du J
    Natural killer cellbased immunotherapy for lung cancer: Challenges and perspectives (Review).
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    September 2021
  2. CHANG CY, Wu KL, Chang YY, Tsai PH, et al
    Amine oxidase, copper containing 3 exerts antimesenchymal transformation and enhances CD4(+) Tcell recruitment to prolong survival in lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  3. ZHANG Y, Yao H, Li Y, Yang L, et al
    Circular RNA TADA2A promotes proliferation and migration via modulating of miR638/KIAA0101 signal in nonsmall cell lung cancer.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    August 2021
  4. KIM MK, Choi MJ, Lee HM, Choi HS, et al
    Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of nonsmall cell lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  5. LIN CC, Liao WT, Yang TY, Lu HJ, et al
    MicroRNA10b modulates cisplatin tolerance by targeting p53 directly in lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  6. ZHANG X, He Y, Jiang Y, Bao Y, et al
    TMEM229A suppresses nonsmall cell lung cancer progression via inactivating the ERK pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  7. LU R, Zhou Q, Ju L, Chen L, et al
    Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    July 2021
  8. ZINNAH KMA, Park SY
    Sensitizing TRAILresistant A549 lung cancer cells and enhancing TRAILinduced apoptosis with the antidepressant amitriptyline.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


  9. ZENG T, Xu M, Zhang W, Gu X, et al
    Autophagy inhibition and microRNA199a5p upregulation in paclitaxelresistant A549/T lung cancer cells.
    Oncol Rep. 2021;46.
    PubMed     Abstract available


    June 2021
  10. BUACHAN P, Namsa-Aid M, Sung HK, Peng C, et al
    Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  11. GAO L, Yang T, Zhang S, Liang Y, et al
    EHF enhances malignancy by modulating AKT and MAPK/ERK signaling in nonsmall cell lung cancer cells.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  12. LI S, Wang H, Ma R, Wang L, et al
    Schisandrin B inhibits epithelialmesenchymal transition and stemness of largecell lung cancer cells and tumorigenesis in xenografts via inhibiting the NFkappaB and p38 MAPK signaling pathways.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    May 2021
  13. GAO Y, Zhang G, Liu J, Li H, et al
    Tissue-specific transplantation antigen P35B functions as an oncogene and is regulated by microRNA-125a-5p in lung cancer.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  14. WANG WJ, Ouyang C, Yu B, Chen C, et al
    Role of hypoxiainducible factor2alpha in lung cancer (Review).
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  15. LIAO H, Liang Y, Kang L, Xiao Y, et al
    miR4543p inhibits nonsmall cell lung cancer cell proliferation and metastasis by targeting TGFB2.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


  16. HE Q, Dong Y, Zhu Y, Ding Z, et al
    TMEM100 induces cell death in nonsmall cell lung cancer via the activation of autophagy and apoptosis.
    Oncol Rep. 2021;45.
    PubMed     Abstract available


    April 2021
  17. LI S, Liu Y, Qiu G, Luo Y, et al
    Emerging roles of circular RNAs in nonsmall cell lung cancer (Review).
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available


  18. HU Y, Cui J, Jin L, Su Y, et al
    LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating MDR1 expression.
    Oncol Rep. 2021;45:1.
    PubMed     Abstract available


    March 2021
  19. YANG XG, Li YY, Zhao DX, Cui W, et al
    Repurposing of a monoamine oxidase A inhibitorheptamethine carbocyanine dye conjugate for paclitaxelresistant nonsmall cell lung cancer.
    Oncol Rep. 2021;45:1306-1314.
    PubMed     Abstract available


  20. LING B, Wei P, Xiao J, Cen B, et al
    Nucleolar and spindleassociated protein 1 promotes nonsmall cell lung cancer progression and serves as an effector of myocyte enhancer factor 2D.
    Oncol Rep. 2021;45:1044-1058.
    PubMed     Abstract available


  21. GU X, Zhang J, Shi Y, Shen H, et al
    ESM1/HIF1alpha pathway modulates chronic intermittent hypoxiainduced nonsmallcell lung cancer proliferation, stemness and epithelialmesenchymal transition.
    Oncol Rep. 2021;45:1226-1234.
    PubMed     Abstract available


    January 2021
  22. ZAAROUR RF, Prasad P, Venkatesh GH, Khouzam RA, et al
    Waterpipe smoke condensate influences epithelial to mesenchymal transition and interferes with the cytotoxic immune response in non-small cell lung cancer cell lines.
    Oncol Rep. 2021 Jan 18. doi: 10.3892/or.2021.7938.
    PubMed     Abstract available


  23. LI M, Chen R, Ji B, Fan C, et al
    Role of ERCC5 polymorphisms in nonsmall cell lung cancer risk and responsiveness/toxicity to cisplatinbased chemotherapy in the Chinese population.
    Oncol Rep. 2021 Jan 14. doi: 10.3892/or.2021.7935.
    PubMed     Abstract available


  24. XIAO L, Mao Y, Tong Z, Zhao Y, et al
    Radiation exposure triggers the malignancy of nonsmall cell lung cancer cells through the activation of visfatin/Snail signaling.
    Oncol Rep. 2021 Jan 8. doi: 10.3892/or.2021.7929.
    PubMed     Abstract available


  25. ZHOU X, Liu B, Ning Q, Xia Z, et al
    Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFRmutated NSCLC cells in vitro and in vivo via STAT3/Bcl2 signaling.
    Oncol Rep. 2021;45:217-229.
    PubMed     Abstract available


    December 2020
  26. ZHU Z, Wu Q, Zhang M, Tong J, et al
    Hsa_circ_0016760 exacerbates the malignant development of nonsmall cell lung cancer by sponging miR1455p/FGF5.
    Oncol Rep. 2020 Dec 14. doi: 10.3892/or.2020.7899.
    PubMed     Abstract available


  27. YANG X, Gao Y, Liu Q, Wan L, et al
    Zoledronic acid resensitises gefitinibresistant lung cancer cells by inhibiting the JAK/STAT3 signalling pathway and reversing epithelialmesenchymal transition.
    Oncol Rep. 2020 Dec 3. doi: 10.3892/or.2020.7881.
    PubMed     Abstract available


    November 2020
  28. ZHAO D, Chen J, Long X, Wang J, et al
    Dose adjustment for tyrosine kinase inhibitors in nonsmall cell lung cancer patients with hepatic or renal function impairment (Review).
    Oncol Rep. 2020 Nov 27. doi: 10.3892/or.2020.7870.
    PubMed     Abstract available


  29. YANG H, Zhan L, Yang T, Wang L, et al
    [Corrigendum] Ski prevents TGFbetainduced EMT and cell invasion by repressing SMADdependent signaling in nonsmall cell lung cancer.
    Oncol Rep. 2020 Nov 25. doi: 10.3892/or.2020.7868.
    PubMed     Abstract available


  30. OUYANG L, Yang M, Wang X, Fan J, et al
    Long noncoding RNA FER1L4 inhibits cell proliferation and promotes cell apoptosis via the PTEN/AKT/p53 signaling pathway in lung cancer.
    Oncol Rep. 2020 Nov 19. doi: 10.3892/or.2020.7861.
    PubMed     Abstract available


  31. WANG L, Wang W
    Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in nonsmall cell lung cancer (Review).
    Oncol Rep. 2020 Nov 13. doi: 10.3892/or.2020.7851.
    PubMed     Abstract available


  32. HASE H, Aoki M, Matsumoto K, Nakai S, et al
    Cancer typeSLCO1B3 promotes epithelialmesenchymal transition resulting in the tumour progression of nonsmall cell lung cancer.
    Oncol Rep. 2020 Nov 6. doi: 10.3892/or.2020.7839.
    PubMed     Abstract available


  33. JIN D, Wu Y, Shao C, Gao Y, et al
    [Retracted] Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human nonsmall lung cancer cells by regulating the YAP pathway.
    Oncol Rep. 2020 Nov 2. doi: 10.3892/or.2020.7830.
    PubMed     Abstract available


  34. REN T, Tang YJ, Wang MF, Wang HS, et al
    Triptolide induces apoptosis through the calcium/calmodulindependent protein kinase kinasebeta/AMPactivated protein kinase signaling pathway in nonsmall cell lung cancer cells.
    Oncol Rep. 2020;44:2288-2296.
    PubMed     Abstract available


    October 2020
  35. CUI XY, Park SH, Park WH
    Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspasedependent apoptosis.
    Oncol Rep. 2020 Oct 21. doi: 10.3892/or.2020.7818.
    PubMed     Abstract available


  36. PARK WH
    Propyl gallate reduces the growth of lung cancer cells through caspasedependent apoptosis and G1 phase arrest of the cell cycle.
    Oncol Rep. 2020 Oct 20. doi: 10.3892/or.2020.7815.
    PubMed     Abstract available


  37. XU L, Qu JL, Song N, Zhang LY, et al
    Biological and clinical significance of flap endonuclease1 in triplenegative breast cancer: Support of metastasis and a poor prognosis.
    Oncol Rep. 2020 Oct 16. doi: 10.3892/or.2020.7812.
    PubMed     Abstract available


    September 2020
  38. ZHAO X, Li M, Dai X, Yang Y, et al
    Downregulation of exosomal miR1273a increases cisplatin resistance of nonsmall cell lung cancer by upregulating the expression of syndecan binding protein.
    Oncol Rep. 2020 Sep 4. doi: 10.3892/or.2020.7753.
    PubMed     Abstract available


  39. WANG X, Zhang G, Cheng Z, Dai L, et al
    Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR98 in lung cancer cells.
    Oncol Rep. 2020;44:1025-1036.
    PubMed     Abstract available


  40. ZHAO Y, Ye X, Chen R, Gao Q, et al
    Sirtuin 7 promotes nonsmall cell lung cancer progression by facilitating G1/S phase and epithelialmesenchymal transition and activating AKT and ERK1/2 signaling.
    Oncol Rep. 2020;44:959-972.
    PubMed     Abstract available


  41. SUN L, Yuan W, Wen G, Yu B, et al
    Parthenolide inhibits human lung cancer cell growth by modulating the IGF1R/PI3K/Akt signaling pathway.
    Oncol Rep. 2020;44:1184-1193.
    PubMed     Abstract available


  42. LI W, Li C, Ma L, Jin F, et al
    Resveratrol inhibits viability and induces apoptosis in the smallcell lung cancer H446 cell line via the PI3K/Akt/cMyc pathway.
    Oncol Rep. 2020 Sep 1. doi: 10.3892/or.2020.7747.
    PubMed     Abstract available


    August 2020
  43. LI D, Wang L, Feng J, Shen YW, et al
    RP11284F21.9 promotes lung carcinoma proliferation and invasion via the regulation of miR6273p/CCAR1.
    Oncol Rep. 2020 Aug 12. doi: 10.3892/or.2020.7732.
    PubMed     Abstract available


  44. GUAN Y, Yang J, Liu X, Chu L, et al
    Long noncoding RNA CBR3 antisense RNA 1 promotes the aggressive phenotypes of nonsmallcell lung cancer by sponging microRNA5093p and competitively upregulating HDAC9 expression.
    Oncol Rep. 2020 Aug 7. doi: 10.3892/or.2020.7719.
    PubMed     Abstract available


  45. LIU X, Huang S, Guan Y, Zhang Q, et al
    Long noncoding RNA OSER1AS1 promotes the malignant properties of nonsmall cell lung cancer by sponging microRNA4333p and thereby increasing Smad2 expression.
    Oncol Rep. 2020;44:599-610.
    PubMed     Abstract available


    July 2020
  46. GAO F, Li M, Zhou L, Liu W, et al
    Xanthohumol targets the ERK1/2Fra1 signaling axis to reduce cyclin D1 expression and inhibit nonsmall cell lung cancer.
    Oncol Rep. 2020 Jul 20. doi: 10.3892/or.2020.7697.
    PubMed     Abstract available


  47. WANG L, Wu L, Pang J
    Long noncoding RNA PSMA3AS1 functions as a microRNA4093p sponge to promote the progression of nonsmall cell lung carcinoma by targeting spindlin 1.
    Oncol Rep. 2020 Jul 15. doi: 10.3892/or.2020.7693.
    PubMed     Abstract available


    June 2020
  48. CHEN J, Lin Q, Ni T, Zhao J, et al
    NLK interacts with 1433zeta to restore the expression of Ecadherin.
    Oncol Rep. 2020;43:1845-1852.
    PubMed     Abstract available


  49. HUANG T, Ren K, Ding G, Yang L, et al
    miR10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway.
    Oncol Rep. 2020;43:1906-1914.
    PubMed     Abstract available


    May 2020
  50. WU X, Li X, Xu G
    Propofol suppresses the progression of nonsmall cell lung cancer via downregulation of the miR215p/MAPK10 axis.
    Oncol Rep. 2020 May 21. doi: 10.3892/or.2020.7619.
    PubMed     Abstract available


  51. DONG S, Men W, Yang S, Xu S, et al
    Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
    Oncol Rep. 2020;43:1437-1450.
    PubMed     Abstract available


    April 2020
  52. EGUCHI R, Wakabayashi I
    HDGF enhances VEGFdependent angiogenesis and FGF2 is a VEGFindependent angiogenic factor in nonsmall cell lung cancer.
    Oncol Rep. 2020 Apr 9. doi: 10.3892/or.2020.7580.
    PubMed     Abstract available


  53. DU W, Sun L, Liu T, Zhu J, et al
    The miR6253p/AXL axis induces nonT790M acquired resistance to EGFRTKI via activation of the TGFbeta/Smad pathway and EMT in EGFRmutant nonsmall cell lung cancer.
    Oncol Rep. 2020 Apr 8. doi: 10.3892/or.2020.7579.
    PubMed     Abstract available


  54. FAN S, Liao Y, Qiu W, Huang Q, et al
    Estrogen promotes the metastasis of nonsmall cell lung cancer via estrogen receptor beta by upregulation of Tolllike receptor 4 and activation of the myd88/NFkappaB/MMP2 pathway.
    Oncol Rep. 2020 Apr 2. doi: 10.3892/or.2020.7574.
    PubMed     Abstract available


  55. YANG MQ, Bai LL, Lei L, Zheng YW, et al
    DEK promotes the proliferation and invasion of lung cancers and indicates poor prognosis in lung adenocarcinomas.
    Oncol Rep. 2020;43:1338-1348.
    PubMed     Abstract available


  56. BAI L, Liang J, Li L, Li E, et al
    Downregulation of MiD49 contributes to tumor growth and metastasis of human pancreatic cancer.
    Oncol Rep. 2020;43:1208-1220.
    PubMed     Abstract available


    March 2020
  57. LV L, Zhang W, Li T, Jiang L, et al
    Hispidulin exhibits potent anticancer activity in vitro and in vivo through activating ER stress in nonsmallcell lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7568.
    PubMed     Abstract available


  58. WANG J, Zhang ZQ, Li FQ, Chen JN, et al
    Triptolide interrupts rRNA synthesis and induces the RPL23MDM2p53 pathway to repress lung cancer cells.
    Oncol Rep. 2020 Mar 30. doi: 10.3892/or.2020.7569.
    PubMed     Abstract available


  59. WEI M, Li J, Qiu J, Yan Y, et al
    Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells.
    Oncol Rep. 2020 Mar 26. doi: 10.3892/or.2020.7566.
    PubMed     Abstract available


  60. HU J, Shang Y, Shi X, Zhang S, et al
    Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in nonsmall cell lung cancer.
    Oncol Rep. 2020 Mar 23. doi: 10.3892/or.2020.7559.
    PubMed     Abstract available


  61. LI F, Cui H, Jin X, Gong X, et al
    Triptolide inhibits epithelialmesenchymal transition and induces apoptosis in gefitinibresistant lung cancer cells.
    Oncol Rep. 2020 Mar 10. doi: 10.3892/or.2020.7542.
    PubMed     Abstract available


  62. CHEN L, Ren P, Zhang Y, Gong B, et al
    Long noncoding RNA GAS5 increases the radiosensitivity of A549 cells through interaction with the miR21/PTEN/Akt axis.
    Oncol Rep. 2020;43:897-907.
    PubMed     Abstract available


    February 2020
  63. CAO F, Wang Z, Feng Y, Zhu H, et al
    lncRNA TPTEP1 competitively sponges miR3285p to inhibit the proliferation of nonsmall cell lung cancer cells.
    Oncol Rep. 2020 Feb 26. doi: 10.3892/or.2020.7522.
    PubMed     Abstract available


  64. LI J, Cui J, Li Z, Fu X, et al
    ORP8 induces apoptosis by releasing cytochrome c from mitochondria in nonsmall cell lung cancer.
    Oncol Rep. 2020 Feb 24. doi: 10.3892/or.2020.7517.
    PubMed     Abstract available


  65. ZHAO L, Wang L, Wang Y, Ma P, et al
    Long noncoding RNA CCAT1 enhances human nonsmall cell lung cancer growth through downregulation of microRNA218.
    Oncol Rep. 2020 Feb 12. doi: 10.3892/or.2020.7500.
    PubMed     Abstract available


  66. LI Y, Yin Y, Ma J, Sun Y, et al
    Combination of AAVmediated NUPR1 knockdown and trifluoperazine induces premature senescence in human lung adenocarcinoma A549 cells in nude mice.
    Oncol Rep. 2020;43:681-688.
    PubMed     Abstract available


  67. CAO PP, Chen WJ, Pang HL, Shen WW, et al
    Effect of CUL4A on the metastatic potential of lung adenocarcinoma to the bone.
    Oncol Rep. 2020;43:662-670.
    PubMed     Abstract available


  68. HU F, Li C, Zheng X, Zhang H, et al
    Lung adenocarcinoma resistance to therapy with EGFRtyrosine kinase inhibitors is related to increased expression of cancer stem cell markers SOX2, OCT4 and NANOG.
    Oncol Rep. 2020;43:727-735.
    PubMed     Abstract available


  69. WANG H, Kanmangne D, Li R, Qian Z, et al
    miR30a3p suppresses the proliferation and migration of lung adenocarcinoma cells by downregulating CNPY2.
    Oncol Rep. 2020;43:646-654.
    PubMed     Abstract available


    January 2020
  70. MIERZEJEWSKA J, Szczygiel A, Anger-Gora N, Rossowska J, et al
    DeOacylated lipooligosaccharide of E. coli B reduces the number of metastatic foci via downregulation of myeloid cell activity.
    Oncol Rep. 2020;43:270-281.
    PubMed     Abstract available


    December 2019
  71. ZHAO C, Zheng S, Yan Z, Deng Z, et al
    CCL18 promotes the invasion and metastasis of breast cancer through Annexin A2.
    Oncol Rep. 2019 Dec 11. doi: 10.3892/or.2019.7426.
    PubMed     Abstract available


    November 2019
  72. ZHANG L, Tao X, Fu Q, Ge C, et al
    Curcumin inhibits cell proliferation and migration in NSCLC through a synergistic effect on the TLR4/MyD88 and EGFR pathways.
    Oncol Rep. 2019;42:1843-1855.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: